id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-292041-a65kfw80	Orienti, Isabella	Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment in COVID-19	2020-05-27		.txt	text/plain	6110	334	34	At present, there is no vaccine or effective standard treatment for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection (or coronavirus disease-19 (COVID-19)), which frequently leads to lethal pulmonary inflammatory responses. Therefore, due to its poly-pharmacology, fenretinide administration by pulmonary formulations may be expected to be protective against acute lung injury (ALI)/ acute respiratory distress syndrome (ARDS) caused by SARS-CoV infection and could represent a useful tool in a multimodal therapy aimed at establishing a rapid anti-inflammatory and antiviral effect. Pulmonary delivery of fenretinide could be a valuable tool in COVID-19 due to the possibility of obtaining a very high drug concentration in the airway and alveolar epithelia, thus triggering a rapid onset of local anti-inflammatory response. Moreover, the pulmonary administration of fenretinide, in combination with the drugs that are currently used in SARS-CoV-2 infection, could represent a new, effective tool in COVID-19 treatment.	./cache/cord-292041-a65kfw80.txt	./txt/cord-292041-a65kfw80.txt